 |
366 Diseases |  |
40 Trials |
|
40 Trials |  |
1659 News |  |
| «12...11121314151617181920212223» |
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Enrollment closed, Metastases: Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Oct 2, 2012
P1/2, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting
- ||| Torisel (temsirolimus) / Pfizer
Enrollment closed: Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Oct 1, 2012
P2, N=108, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=24, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting N=45 --> 24
- Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=24, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=45 --> 24 Recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
New P2 trial, Journal, Metastases: Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 17, 2012
P2, N=28, Recruiting, Sponsor: University of California, San Francisco
- Torisel (temsirolimus) / Pfizer
Trial initiation date, Metastases: CCI-779 in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 6, 2012
P1, N=15, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
Recruiting --> Completed Initiation date: Jul 1998 --> Jan 2001
- Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: CCI-779 in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 6, 2012
P1, N=15, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
Initiation date: Jul 1998 --> Jan 2001 N=20 --> 15
- Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: CCI-779 in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 6, 2012
P1, N=15, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
N=20 --> 15 Active, not recruiting --> Completed
- ||||| Torisel (temsirolimus) / Pfizer
Trial initiation date: Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (clinicaltrials.gov) - Aug 2, 2012
P3, N=216, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Initiation date: Nov 2008 --> Sep 2009
- | Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Roche
New P2 trial: STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Jul 26, 2012
P2, N=88, Recruiting, Sponsor: Mathias Witzens-Harig
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment closed, Metastases: CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer (clinicaltrials.gov) - Jul 19, 2012
P1/2, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Nov 2008 --> Sep 2009 Completed --> Active, not recruiting
- |||||||||| Torisel (temsirolimus) / Pfizer
New P3 trial: RAY : Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy (clinicaltrials.gov) - Jul 18, 2012
P3, N=280, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Enrollment closed, Metastases: Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma (clinicaltrials.gov) - Jul 17, 2012
P2, N=172, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting Recruiting --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer
Trial termination: Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer (clinicaltrials.gov) - Jul 12, 2012
P1/2, N=5, Terminated, Sponsor: Sandy Srinivas
Recruiting --> Active, not recruiting Recruiting --> Terminated; Decision by funding sponsor due to poor accrual
- Torisel (temsirolimus) / Pfizer
Enrollment change: Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer (clinicaltrials.gov) - Jul 12, 2012
P1/2, N=5, Terminated, Sponsor: Sandy Srinivas
Recruiting --> Terminated; Decision by funding sponsor due to poor accrual N=40 --> 5
- Torisel (temsirolimus) / Pfizer
Enrollment closed, Metastases: Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 12, 2012
P1, N=25, Active, not recruiting, Sponsor: University of California, San Francisco
N=40 --> 5 Recruiting --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer
Enrollment closed: Hepatocellular Carcinoma (HCC)_Torisel_ (clinicaltrials.gov) - Jul 9, 2012
P1/2, N=50, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Enrollment change, Metastases: Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib (clinicaltrials.gov) - Jul 5, 2012
P2, N=22, Completed, Sponsor: Central European Society for Anticancer Drug Research
Recruiting --> Active, not recruiting N=108 --> 22
- Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Trial completion, Metastases: Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib (clinicaltrials.gov) - Jul 5, 2012
P2, N=22, Completed, Sponsor: Central European Society for Anticancer Drug Research
N=108 --> 22 Recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Trial completion: Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies (clinicaltrials.gov) - Jun 20, 2012
P1, N=26, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Completed Active, not recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Trial completion: Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies (clinicaltrials.gov) - Jun 20, 2012
P1, N=28, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD), Torisel (temsirolimus) / Pfizer
New P1 trial, Combination therapy, Surgery, Metastases: Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery (clinicaltrials.gov) - Jun 19, 2012
P1, N=48, Recruiting, Sponsor: National Cancer Institute (NCI)
- Torisel (temsirolimus) / Pfizer
Trial completion, Combination therapy: Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Jun 16, 2012
P1, N=56, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma (clinicaltrials.gov) - Jun 12, 2012
P2, N=35, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- rhIL-15 / National Cancer Institute
Enrollment change, Metastases: A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer (clinicaltrials.gov) - Jun 6, 2012
P1, N=18, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=39 --> 18
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
New P2 trial, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Jun 6, 2012
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Torisel (temsirolimus) / Pfizer
New P1/2 trial, Combination therapy, Metastases: Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma (clinicaltrials.gov) - Jun 5, 2012
P1/2, N=136, Recruiting, Sponsor: University of Regensburg
- Torisel (temsirolimus) / Pfizer
New P1 trial, Combination therapy: A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma (clinicaltrials.gov) - Jun 5, 2012
P1, N=30, Suspended, Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
- Torisel (temsirolimus) / Pfizer
Trial completion: Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma (clinicaltrials.gov) - Jun 5, 2012
P1/2, N=68, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=39 --> 18 Active, not recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
New P2 trial: TOR-AML: Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia (clinicaltrials.gov) - May 31, 2012
P2, N=218, Recruiting, Sponsor: Christian Brandts MD
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial withdrawal, Combination therapy: A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - May 8, 2012
P1, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Withdrawn
- Torisel (temsirolimus) / Pfizer, Zelboraf (vemurafenib) / Roche
New P1 trial, Combination therapy, Metastases: Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (clinicaltrials.gov) - May 8, 2012
P1, N=114, Recruiting, Sponsor: M.D. Anderson Cancer Center
- |||| Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Apr 24, 2012
P2, N=82, Completed, Sponsor: Pfizer
Completed --> Withdrawn Active, not recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Trial termination: Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas (clinicaltrials.gov) - Apr 18, 2012
P1/2, N=17, Terminated, Sponsor: New Mexico Cancer Care Alliance
Active, not recruiting --> Completed Recruiting --> Terminated; Original PI left institution and sponsor decided to end support.
- Torisel (temsirolimus) / Pfizer
Enrollment change: Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas (clinicaltrials.gov) - Apr 18, 2012
P1/2, N=17, Terminated, Sponsor: New Mexico Cancer Care Alliance
Recruiting --> Terminated; Original PI left institution and sponsor decided to end support. N=30 --> 17
- Torisel (temsirolimus) / Pfizer
Trial completion: CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Apr 17, 2012
P2, N=89, Completed, Sponsor: National Cancer Institute (NCI)
N=30 --> 17 Terminated --> Completed
- Torisel (temsirolimus) / Pfizer
Enrollment closed: Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer (clinicaltrials.gov) - Apr 16, 2012
P2, N=40, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Terminated --> Completed Recruiting --> Active, not recruiting
- | Torisel (temsirolimus) / Pfizer
New P2 trial, Metastases: Temsirolimus as Second-line Therapy in HCC (clinicaltrials.gov) - Mar 28, 2012
P2, N=25, Recruiting, Sponsor: University of Tennessee Cancer Institute
- Votrient (pazopanib) / Novartis, BeiGene, Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 25, 2012
P1, N=8, Completed, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting N=30 --> 8
- Torisel (temsirolimus) / Pfizer
Enrollment open, Combination therapy, Metastases: Temsirolimus in Combination With Metformin in Patients With Advanced Cancers (clinicaltrials.gov) - Mar 25, 2012
P1, N=104, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=30 --> 8 Not yet recruiting --> Recruiting
- Votrient (pazopanib) / Novartis, BeiGene, Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 25, 2012
P1, N=8, Completed, Sponsor: University of California, Davis
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy (clinicaltrials.gov) - Mar 20, 2012
P1/2, N=22, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed N=34 --> 22
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment closed, Metastases: Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy (clinicaltrials.gov) - Mar 20, 2012
P1/2, N=22, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
N=34 --> 22 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Enrollment open, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Mar 15, 2012
P1, N=216, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
New P1 trial, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Mar 11, 2012
P1, N=216, Recruiting, Sponsor: M.D. Anderson Cancer Center
- trebananib (AMG 386) / Amgen, Torisel (temsirolimus) / Pfizer
New P1 trial, Surgery, Metastases: Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 6, 2012
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- Zolinza (vorinostat) / Merck (MSD), Torisel (temsirolimus) / Pfizer
Trial initiation date, Combination therapy, Metastases: Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Mar 4, 2012
P1, N=29, Recruiting, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Initiation date: Sep 2010 --> Feb 2012
- Zolinza (vorinostat) / Merck (MSD), Torisel (temsirolimus) / Pfizer
Enrollment open, Combination therapy, Metastases: Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Mar 4, 2012
P1, N=29, Recruiting, Sponsor: Roswell Park Cancer Institute
Initiation date: Sep 2010 --> Feb 2012 Not yet recruiting --> Recruiting
- Torisel (temsirolimus) / Pfizer
Biomarker, Enrollment closed, Metastases: Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Mar 4, 2012
P=N/A, N=11, Active, not recruiting, Sponsor: St. Joseph's Healthcare Hamilton
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy, Metastases: Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer (clinicaltrials.gov) - Feb 28, 2012
P1, N=278, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=230 --> 278